Marshall Wace, LLP Adagio Therapeutics, Inc. Transaction History
Marshall Wace, LLP
- $77.3 Billion
- Q3 2024
A detailed history of Marshall Wace, LLP transactions in Adagio Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 120,444 shares of ADGI stock, worth $398,669. This represents 0.0% of its overall portfolio holdings.
Number of Shares
120,444
Previous 786,899
84.69%
Holding current value
$398,669
Previous $2.6 Million
84.72%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding ADGI
# of Institutions
78Shares Held
63.9MCall Options Held
2.3KPut Options Held
2.1K-
Lee Ainslie Maverick Capital LTD | Dallas, Tx11.8MShares$38.9 Million0.81% of portfolio
-
Deep Track Capital, LP Greenwich, CT11MShares$36.3 Million1.34% of portfolio
-
M28 Capital Management LP Stamford, CT9.25MShares$30.6 Million29.1% of portfolio
-
Black Rock Inc. New York, NY4.47MShares$14.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.37MShares$14.5 Million0.0% of portfolio
About Adagio Therapeutics, Inc.
- Ticker ADGI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 108,831,000
- Market Cap $505M
- Description
- Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...